HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Roger J. F. Baskett David B. Ross Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Baskett, R. J. F. Articles by Ross, D. B. Search for Related Content PubMed PubMed Citation Articles by Baskett, R. J. F. Articles by Ross, D. B. Related Collections Congenital - acyanotic Valve disease Related Article

J Thorac Cardiovasc Surg 2003;126:232-238
© 2003 The American Association for Thoracic Surgery

Surgery for congenital heart disease

Human leukocyte antigen-DR and ABO mismatch are associated with accelerated homograft valve failure in children: implications for therapeutic interventions

^a Maritime Heart Centre & Division of Cardiac Surgery,^a Department of Surgery, Dalhousie University, Halifax, Nova Scotia, Canada;
^b Department of Cardiology,^b IWK Grace Hospital, Dalhousie University, Halifax, Nova Scotia, Canada
^c Division of Cardiac Surgery,^c University of Alberta, Edmonton, Alberta, Canada

Read at the Twenty-eighth Annual Meeting of The Western Thoracic Surgical Association, Big Sky, Mont, June 19-22, 2002.

Received for publication July 10, 2002; accepted for publication December 30, 2002.

^* Address for reprints: Roger J. F. Baskett, MA, MD, Maritime Heart Centre, Room 2269 2nd Floor, 1796 Summer St., Halifax, Nova Scotia B3H 3A7 Canada
RogerBaskett{at}hotmail.com

OBJECTIVE: This study examines the incidence and factors associated with the failure of homograft valves and identifies those factors that are modifiable.

METHODS: From 1990 to 2001, 96 homograft valves were implanted in the right ventricular outflow tract of 83 children (mean age 5.1 ± 5.6 years). Clinical and blinded serial echocardiographic follow-up was performed on all 90 valves in the 77 survivors.

RESULTS: Eighteen homograft valves were replaced as the result of pulmonary insufficiency (3), stenosis (9), or both (6). Freedom from reoperation was 71% at 9 years (95% confidence interval, 58%-84%). Forty-eight valves developed progressive pulmonary insufficiency of at least 2 grades, 26 valves developed transvalvular gradients of 50 mm Hg or greater, and 14 of these valves were also insufficient. The freedom from echocardiographic failure (progressive pulmonary insufficiency 2 grades or 50 mm Hg gradient) was only 27% at 5 years (95% confidence interval, 17%-37%). In a multivariate analysis (Cox regression), use of an aortic homograft (P = .001) and short antibiotic preservation time (P = .04) were associated with reoperation. Younger age (P = .01), ABO mismatch (P = .04), and diagnosis (P = .005) were associated with echocardiographic failure. In the subanalysis of patients with human leukocyte antigen typing, age (P = .002), aortic homograft (P = .04), and human leukocyte antigen-DR mismatch (P = .03) were associated with echocardiographic valve failure.

CONCLUSION: Many homografts rapidly become insufficient and require replacement. In our analysis of both reoperation and echocardiographic failure, several immunologic factors are consistently associated with homograft failure. Matching for human leukocyte antigen-DR, blood group, and avoiding short preservation times (thus minimizing antigenicity) offers the potential to extend the life of these valves.

This article has been cited by other articles:

				J. Horer, T. Hanke, U. Stierle, J. J.M. Takkenberg, A. J.J.C. Bogers, W. Hemmer, J. G. Rein, R. Hetzer, M. Hubler, D. R. Robinson, et al. Homograft performance in children after the Ross operation. Ann. Thorac. Surg., August 1, 2009; 88(2): 609 - 615. [Abstract] [Full Text] [PDF]

				B. Feingold, P. D. Wearden, V. O. Morell, D. Galvis, and C. Galambos Expression of A and B Blood Group Antigens on Cryopreserved Homografts Ann. Thorac. Surg., January 1, 2009; 87(1): 211 - 214. [Abstract] [Full Text] [PDF]

				R. C. Elkins, D. M. Thompson, M. M. Lane, C. C. Elkins, and M. D. Peyton Ross operation: 16-year experience J. Thorac. Cardiovasc. Surg., September 1, 2008; 136(3): 623 - 630. [Abstract] [Full Text] [PDF]

				E. Hickey, S. M. Langley, O. Allemby-Smith, S. A. Livesey, and J. L. Monro Subcoronary Allograft Aortic Valve Replacement: Parametric Risk-Hazard Outcome Analysis to a Minimum of 20 Years Ann. Thorac. Surg., November 1, 2007; 84(5): 1564 - 1570. [Abstract] [Full Text] [PDF]

				E. Troost, B. Meyns, W. Daenen, F. Van de Werf, M. Gewillig, K. Van Deyk, P. Moons, and W. Budts Homograft survival after tetralogy of Fallot repair: determinants of accelerated homograft degeneration Eur. Heart J., October 2, 2007; 28(20): 2503 - 2509. [Abstract] [Full Text] [PDF]

				T. Karamlou, E. H. Blackstone, J. A. Hawkins, M. L. Jacobs, K. R. Kanter, J. W. Brown, C. Mavroudis, C. A. Caldarone, W. G. Williams, B. W. McCrindle, et al. Can pulmonary conduit dysfunction and failure be reduced in infants and children less than age 2 years at initial implantation? J. Thorac. Cardiovasc. Surg., October 1, 2006; 132(4): 829 - 838. [Abstract] [Full Text] [PDF]

				T. Oosterhof, F. J. Meijboom, H. W. Vliegen, M. G. Hazekamp, A. H. Zwinderman, B. J. Bouma, A. P.J. van Dijk, and B. J.M. Mulder Long-term follow-up of homograft function after pulmonary valve replacement in patients with tetralogy of Fallot Eur. Heart J., June 2, 2006; 27(12): 1478 - 1484. [Abstract] [Full Text] [PDF]

				D. G. Pennington The Impact of New Technology on Cardiothoracic Surgical Practice Ann. Thorac. Surg., January 1, 2006; 81(1): 10 - 18. [Full Text] [PDF]

				Z. Tavakkol, S. Gelehrter, C. S. Goldberg, E. L. Bove, E. J. Devaney, and R. G. Ohye Superior Durability of Synergraft Pulmonary Allografts Compared With Standard Cryopreserved Allografts Ann. Thorac. Surg., November 1, 2005; 80(5): 1610 - 1614. [Abstract] [Full Text] [PDF]

				B. Meyns, R. Jashari, M. Gewillig, L. Mertens, A. Komarek, E. Lesaffre, W. Budts, and W. Daenen Factors influencing the survival of cryopreserved homografts. The second homograft performs as well as the first Eur. J. Cardiothorac. Surg., August 1, 2005; 28(2): 211 - 216. [Abstract] [Full Text] [PDF]

				H. Feier, F. Collart, O. Ghez, A. Riberi, T. Caus, B. Kreitmann, and D. Metras Risk Factors, Dynamics, and Cutoff Values for Homograft Stenosis After the Ross Procedure Ann. Thorac. Surg., May 1, 2005; 79(5): 1669 - 1675. [Abstract] [Full Text] [PDF]

				T. Karamlou, R. M. Ungerleider, B. Alsoufi, G. Burch, M. Silberbach, M. Reller, and I. Shen Oversizing pulmonary homograft conduits does not significantly decrease allograft failure in children Eur. J. Cardiothorac. Surg., April 1, 2005; 27(4): 548 - 553. [Abstract] [Full Text] [PDF]

				S. R. Meyer, P. M. Campbell, J. M. Rutledge, A. M. Halpin, L. E. Hawkins, J. R.T. Lakey, I. M. Rebeyka, and D. B. Ross Use of an allograft patch in repair of hypoplastic left heart syndrome may complicate future transplantation Eur. J. Cardiothorac. Surg., April 1, 2005; 27(4): 554 - 560. [Abstract] [Full Text] [PDF]

				J.F. M. Bechtel, J. Gellissen, A. W. Erasmi, M. Petersen, A. Hiob, U. Stierle, and H.-H. Sievers Mid-term findings on echocardiography and computed tomography after RVOT-reconstruction: comparison of decellularized (SynerGraft) and conventional allografts Eur. J. Cardiothorac. Surg., March 1, 2005; 27(3): 410 - 415. [Abstract] [Full Text] [PDF]

				D. K. Hooper, J. A. Hawkins, T. C. Fuller, T. Profaizer, and R. E. Shaddy Panel-Reactive Antibodies Late After Allograft Implantation in Children Ann. Thorac. Surg., February 1, 2005; 79(2): 641 - 644. [Abstract] [Full Text] [PDF]

				C. Stamm, A. Khosravi, N. Grabow, K. Schmohl, N. Treckmann, A. Drechsel, M. Nan, K.-P. Schmitz, A. Haubold, and G. Steinhoff Biomatrix/Polymer Composite Material for Heart Valve Tissue Engineering Ann. Thorac. Surg., December 1, 2004; 78(6): 2084 - 2093. [Abstract] [Full Text] [PDF]

				P. G. Hogan and M. F. O'Brien Improving the allograft valve: does the immune response matter? J. Thorac. Cardiovasc. Surg., November 1, 2003; 126(5): 1251 - 1253. [Full Text] [PDF]